Dylan Zylla1,2, Grant Steele3,4, Alice Shapiro3,4, Sara Richter3,5, Pankaj Gupta6. 1. Frauenshuh Cancer Center, Park Nicollet Oncology Research and HealthPartners Institute, 3800 Park Nicollet Blvd, Minneapolis, MN, 55416, USA. dylan.zylla@parknicollet.com. 2. HealthPartners Institute, Minneapolis, MN, USA. dylan.zylla@parknicollet.com. 3. Frauenshuh Cancer Center, Park Nicollet Oncology Research and HealthPartners Institute, 3800 Park Nicollet Blvd, Minneapolis, MN, 55416, USA. 4. HealthPartners Institute, Minneapolis, MN, USA. 5. Professional Data Analysts, Inc., Minneapolis, MN, USA. 6. Hematology/Oncology Section, Department of Medicine, Minneapolis VA Health Care System, Minneapolis, USA.
Abstract
PURPOSE: Patients with advanced cancers frequently experience pain. Opioids are commonly prescribed to treat cancer-related pain, but their use might be associated with undesirable consequences including adverse effects and tumor progression, resulting in increased heath care utilization and shorter survival. We examined these possibilities in a large cohort of patients diagnosed with ten common advanced malignancies. METHODS: We identified 1386 newly diagnosed patients with stage IV non-hematologic malignancies from 2005 to 2013 and ascertained opioid utilization within 90 days of starting anti-cancer treatment using electronic medical record and tumor registry data. Opioid utilization was stratified into low opioid (LO; < 5 mg oral morphine equivalents (OME)/day) and high opioid (HO; ≥ 5 mg OME/day). Health care utilization included tallies of emergency room, urgent care, and inpatient visits. The association of opioid use, tumor type prognosis, age, and gender with overall survival was analyzed in univariate and multivariate models. RESULTS: HO use patients (n = 624) had greater health care utilization compared to LO use patients (n = 762; p < 0.05). HO use patients also had shorter survival (median survival, 5.5 vs 12.4 months; p < 0.0001). On multivariate analysis, HO use remained associated with shorter overall survival (HR 1.4; 95% CI, 1.3-1.6; p < 0.0001) after adjusting for age, gender, and prognostic group. CONCLUSIONS: In advanced cancer patients, HO use is associated with greater health care utilization and shorter survival. Prospective studies using opioid-sparing approaches are indicated, to confirm these retrospective findings and to evaluate if these undesirable effects associated with opioid use can be mitigated.
PURPOSE:Patients with advanced cancers frequently experience pain. Opioids are commonly prescribed to treat cancer-related pain, but their use might be associated with undesirable consequences including adverse effects and tumor progression, resulting in increased heath care utilization and shorter survival. We examined these possibilities in a large cohort of patients diagnosed with ten common advanced malignancies. METHODS: We identified 1386 newly diagnosed patients with stage IV non-hematologic malignancies from 2005 to 2013 and ascertained opioid utilization within 90 days of starting anti-cancer treatment using electronic medical record and tumor registry data. Opioid utilization was stratified into low opioid (LO; < 5 mg oral morphine equivalents (OME)/day) and high opioid (HO; ≥ 5 mg OME/day). Health care utilization included tallies of emergency room, urgent care, and inpatient visits. The association of opioid use, tumor type prognosis, age, and gender with overall survival was analyzed in univariate and multivariate models. RESULTS: HO use patients (n = 624) had greater health care utilization compared to LO use patients (n = 762; p < 0.05). HO use patients also had shorter survival (median survival, 5.5 vs 12.4 months; p < 0.0001). On multivariate analysis, HO use remained associated with shorter overall survival (HR 1.4; 95% CI, 1.3-1.6; p < 0.0001) after adjusting for age, gender, and prognostic group. CONCLUSIONS: In advanced cancerpatients, HO use is associated with greater health care utilization and shorter survival. Prospective studies using opioid-sparing approaches are indicated, to confirm these retrospective findings and to evaluate if these undesirable effects associated with opioid use can be mitigated.
Entities:
Keywords:
Analgesics; Health care utilization; Neoplasms; Opioid; Survival
Authors: Marie T Fallon; Eberhard Albert Lux; Robert McQuade; Sandro Rossetti; Raymond Sanchez; Wei Sun; Stephen Wright; Aron H Lichtman; Elena Kornyeyeva Journal: Br J Pain Date: 2017-05-17
Authors: M H J van den Beuken-van Everdingen; J M de Rijke; A G Kessels; H C Schouten; M van Kleef; J Patijn Journal: Ann Oncol Date: 2007-03-12 Impact factor: 32.976
Authors: David M Kern; Siting Zhou; Soheil Chavoshi; Ozgur Tunceli; Mark Sostek; Joseph Singer; Robert J LoCasale Journal: Am J Manag Care Date: 2015-03-01 Impact factor: 2.229
Authors: Kalpna Gupta; Smita Kshirsagar; Liming Chang; Robert Schwartz; Ping-Y Law; Doug Yee; Robert P Hebbel Journal: Cancer Res Date: 2002-08-01 Impact factor: 12.701
Authors: Jessica D McDermott; Megan Eguchi; William A Stokes; Arya Amini; Mohammad Hararah; Ding Ding; Allison Valentine; Cathy J Bradley; Sana D Karam Journal: Otolaryngol Head Neck Surg Date: 2018-11-06 Impact factor: 3.497
Authors: Jason W Boland; Victoria Allgar; Elaine G Boland; Mike I Bennett; Stein Kaasa; Marianne Jensen Hjermstad; Miriam Johnson Journal: Eur J Clin Pharmacol Date: 2019-12-21 Impact factor: 2.953
Authors: Bruce H Chamberlain; Michelle Rhiner; Neal E Slatkin; Nancy Stambler; Robert J Israel Journal: J Pain Res Date: 2021-09-01 Impact factor: 3.133